CHAD organised together with the EMHA Cluster Headache Special Interest Group [CHSIG], which will be held on March 21st in Paris. The draft programme is attached. The theme for this year will be “ Shaping a painless future for Cluster Headache”. During the event different important topics regarding CH will be discussed such as personal […]
Cluster Headache Awareness Day 2018 ( CHAD ) Read More »
The European Medicines Agency’s experts in medicines safety, the Pharmacovigilance Risk Assessment Committee (PRAC) are recommending new measures to avoid exposure of babies to valproate medicines in the womb. Babies exposed are at risk of malformations and developmental problems. The PRAC examined the available evidence and consulted widely with healthcare professionals and with patients, including women
PRAC recommends new measures to avoid valproate exposure in pregnancy Read More »
On the 24 of January 2018, from 10.00 to 12:00, will be celebrated inside the European Parliament (Room ASP A3F383) a meeting focused on: “Making Visible The Invisible On Headache Pain: Sharing Successful Experiences Across Europe”. Register here for the 24 of January 2018. The initiative is promoted by Active Citizenship Network in partnership with the European Headache Alliance (EMHA), and it will
Making Visible The Invisible On Headache Pain Read More »
Laboratory-made antibody Erenumab blocks neural brain pathway and is first new treatment for attacks approved in 20 years A new migraine drug that can halve the length of time sufferers are laid low by the debilitating condition has been hailed as an “incredibly important” advance. Erenumab, a laboratory-made antibody that blocks a neural brain pathway
New Migraine drug hailed as “Incredibly important” breakthrough Read More »
Global Hybrid Educational meeting organized by Novartis Pharma AG with life broadcast via CGRP forum. Globally renowned experts share the latest in #Mirgaine research. http://www.cgrpforum.org/migraine-science-day/ #MigraineAwareness
Migraine Science Day Scientific Hybrid Standalone- Novartis Read More »
Improving Health, Global Patient Advocacy Dialogue meeting; Monday 25th and Tuesday 26th September at the Teva office in Amsterdam. The meeting will be hosted at Teva’s Amsterdam office which is located at Piet Heinkade 107, 1019 GM Amsterdam, The Netherlands Draft Agenda Monday 25th September 2017 10.00 – 12noon Welcome, Introductions Recap from March Mtg, Washington DC 12noon – 1pm Lunch 1.00 – 3.30pm Patient Policy: What
Improving Health Global Patient Meeting – TEVA Read More »
Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities
Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of
Positive Phase III data for migraine drug Fremanezumab Read More »
